Fröhling S - Search Results

1

TelomereHunter - in silico estimation of telomere content and composition from cancer genomes.

Feuerbach L, Sieverling L, Deeg KI, Ginsbach P, Hutter B, Buchhalter I, Northcott PA, Mughal SS, Chudasama P, Glimm H, Scholl C, Lichter P, Fröhling S, Pfister SM, Jones DTW, Rippe K, Brors B. Feuerbach L, et al. Among authors: frohling s. BMC Bioinformatics. 2019 May 28;20(1):272. doi: 10.1186/s12859-019-2851-0. BMC Bioinformatics. 2019. PMID: 31138115 Free PMC article.

2

Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.

Fischer K, Scholl C, Sàlat J, Fröhling S, Schlenk R, Bentz M, Stilgenbauer S, Lichter P, Döhner H. Fischer K, et al. Among authors: frohling s. Blood. 1996 Nov 15;88(10):3962-71. Blood. 1996. PMID: 8916963 Free article.

3

Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias.

Fischer K, Fröhling S, Scherer SW, McAllister Brown J, Scholl C, Stilgenbauer S, Tsui LC, Lichter P, Döhner H. Fischer K, et al. Among authors: frohling s. Blood. 1997 Mar 15;89(6):2036-41. Blood. 1997. PMID: 9058725 Free article.

4

Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders.

Döhner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, Scholl C, Fröhling S, Cuneo A, Tsui LC, Lichter P, Scherer SW, Döhner H. Döhner K, et al. Among authors: frohling s. Blood. 1998 Dec 1;92(11):4031-5. Blood. 1998. PMID: 9834205 Free article.

5

Genetics of myeloid malignancies: pathogenetic and clinical implications.

Fröhling S, Scholl C, Gilliland DG, Levine RL. Fröhling S, et al. J Clin Oncol. 2005 Sep 10;23(26):6285-95. doi: 10.1200/JCO.2005.05.010. J Clin Oncol. 2005. PMID: 16155011 Review.

6

Deregulation of signaling pathways in acute myeloid leukemia.

Scholl C, Gilliland DG, Fröhling S. Scholl C, et al. Among authors: frohling s. Semin Oncol. 2008 Aug;35(4):336-45. doi: 10.1053/j.seminoncol.2008.04.004. Semin Oncol. 2008. PMID: 18692684 Review.

7

STK33 kinase is not essential in KRAS-dependent cells--letter.

Fröhling S, Scholl C. Fröhling S, et al. Cancer Res. 2011 Dec 15;71(24):7716; author reply 7717. doi: 10.1158/0008-5472.CAN-11-2495. Epub 2011 Nov 29. Cancer Res. 2011. PMID: 22127923 No abstract available.

8

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Azoitei N, et al. Among authors: frohling s. J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26. J Exp Med. 2012. PMID: 22451720 Free PMC article.

9

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Dietrich S, et al. Among authors: frohling s. J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690412 No abstract available.

10

Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.

Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Stolze B, et al. Among authors: frohling s. Sci Rep. 2015 Feb 23;5:8535. doi: 10.1038/srep08535. Sci Rep. 2015. PMID: 25705018 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

298 results

Search Page